Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)

Exclusion Criteria

• •Has confirmed nodular lymphocyte-predominant Hodgkin Lymphoma (HL)
• •Has an uncontrolled intercurrent cardiovascular illness
• •Has received prior therapy with an anti-programmed cell death 1 protein (PD-1), anti-programmed cell death ligand 1 protein (PD-L1), or anti- programmed cell death ligand 2 protein (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
• •Has received or is expected to receive a live or live-attenuated vaccine within 30 days before the first dose of study intervention
• •Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention
• •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
• •Has a known additional malignancy that is progressing or has required active treatment within the past 5 years
• •Has radiographically detectable central nervous system metastases and/or carcinomatous meningitis
• •Has an active autoimmune disease that has required systemic treatment in past 2 years
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has a history or current evidence of pulmonary fibrosis
• •Has had an allogenic tissue/solid organ transplant